Your pps estimates seem to be a little high considering it may be a few years or more until 2-73 is approved and then hits the market (if it passes all the appropriate phases). As you said, big pharm companies are typically worth 20 x earnings so AVXL pps will most likely not be in the $350 range until solid earnings are released (2020?). In my opinion, the $150 pps could happen if and when the FDA approves 2-73 for release, but again, that may even be a few years off from now. $150 next summer would require some substantially good news and in my opinion even a full, good phase 2b report couldn't drive the price that high. Then again, Wall Street scammers pumped AXON and there pps went up to $31 a share on literally nothing. Maybe once AVXL is up listed and gains respect because of scientific results, those same AXON investors will jump on board and drive the AVXL pps through the roof. I'm long on AVXL but I'm realistic on long term higher pps because of the time the FDA, production, and sales process takes. No worries, I've got a solid jump and will wait it out,
News 
Market Data 
Discover 
AI
